Online inquiry

IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6882MR)

This product GTTS-WQ6882MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CX3CL1 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_002996.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6376
UniProt ID P78423
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6882MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6175MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CP-751871
GTTS-WQ3100MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA APG-101
GTTS-WQ1750MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ADCT-301
GTTS-WQ5353MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ9651MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ13712MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RC48
GTTS-WQ343MR IVTScrip™ mRNA-Anti-CD27, 1F5(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 1F5
GTTS-WQ12079MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MOR-00208
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW